| 35.01 -0.98 (-2.72%) | 07-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 47.38  |
1-year : | 51.49 |
| Resists | First : | 40.56 |
Second : | 44.09 |
| Pivot price | 38.45  |
|||
| Supports | First : | 34.86 |
Second : | 29 |
| MAs | MA(5) : | 36.12 |
MA(20) : | 38.77 |
| MA(100) : | 31.74 |
MA(250) : | 32.92 |
|
| MACD | MACD : | 0.2 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 10.9 |
D(3) : | 14 |
| RSI | RSI(14): 42.4 |
|||
| 52-week | High : | 46 | Low : | 22.23 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AGIO ] has closed above bottom band by 11.6%. Bollinger Bands are 16.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 36.06 - 36.25 | 36.25 - 36.42 |
| Low: | 34.39 - 34.63 | 34.63 - 34.84 |
| Close: | 34.64 - 35.01 | 35.01 - 35.32 |
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Thu, 30 Jul 2026
AGIO: Q2 2026 revenue surged to $44.7M, with strong AQVESME launch and narrowed net loss - TradingView
Thu, 30 Jul 2026
AGIO: Q2 2026 revenue tripled year-over-year, fueled by AQVESME launch and robust pipeline progress - TradingView
Thu, 30 Jul 2026
Is Agios Pharmaceuticals (AGIO) a Value Opportunity After Q2 Ear - GuruFocus
Thu, 30 Jul 2026
Earnings Flash (AGIO) Agios Pharmaceuticals, Inc. Reports Q2 Revenue $44.7M, vs. FactSet Est of $26.4M - marketscreener.com
Thu, 30 Jul 2026
Earnings Flash (AGIO) Agios Pharmaceuticals Posts Q2 Net Loss $1.69 a Share, vs. FactSet Est of $1.71 Loss - marketscreener.com
Thu, 30 Jul 2026
Agios Pharmaceuticals: Q2 Earnings Snapshot - kens5.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 59 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 109.3 (%) |
| Shares Short | 6,630 (K) |
| Shares Short P.Month | 6,900 (K) |
| EPS | -7.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.69 |
| Profit Margin | 0 % |
| Operating Margin | -530.4 % |
| Return on Assets (ttm) | -21.7 % |
| Return on Equity (ttm) | -32.9 % |
| Qtrly Rev. Growth | 137.6 % |
| Gross Profit (p.s.) | -4.86 |
| Sales Per Share | 1.11 |
| EBITDA (p.s.) | -7.91 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -380 (M) |
| Levered Free Cash Flow | -267 (M) |
| PE Ratio | -4.83 |
| PEG Ratio | 0 |
| Price to Book value | 1.87 |
| Price to Sales | 31.52 |
| Price to Cash Flow | -5.48 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|